Aging is associated with the development of chronic diseases such as insulin resistance and type 2 diabetes. A reduction in mitochondrial fat oxidation is postulated to be a key factor contributing to the progression of these diseases. Our aim was to investigate the contribution of impaired mitochondrial fat oxidation towards age-related disease. Mice deficient for malonyl CoA decarboxylase (MCD-/-), a mouse model of reduced fat oxidation, were allowed to age while lifespan and a number of physiological parameters (glucose tolerance, insulin tolerance, indirect calorimetry) were assessed. Decreased fat oxidation in MCD-/-mice resulted in the accumulation of lipid intermediates in peripheral tissues, but this was not associated with a worsening of age-associated insulin resistance and conversely, improved longevity. This improvement was associated with reduced oxidative stress and reduced acetylation of the antioxidant enzyme, superoxide dismutase 2 (SOD2) in muscle but not the liver of MCD-/-mice.
INTRODUCTION
It is well established that aging is associated with the development of a number of chronic diseases, some of which include insulin resistance, type 2 diabetes, and cardiovascular disease (1; 2). The development of chronic diseases with aging is due in part to a reduction in mitochondrial function, which manifests as a decline in fatty acid oxidative capacity, and is believed to result in the accumulation of intracellular lipid intermediates that interfere with normal organ function (3; 4).
Malonyl CoA decarboxylase (MCD), is an important enzyme involved in the regulation of fatty acid oxidation, since it controls cellular levels of malonyl CoA, a potent endogenous inhibitor of carnitine palmitoyl transferase 1, the rate-limiting enzyme of mitochondrial fatty acid uptake (5) . We have shown that acute inhibition of MCD decreases fatty acid oxidation rates in the heart and improves functional recovery during reperfusion following ischemia (6) . We observed similar results in a mouse model of MCD deficiency (MCD-/-) (7) , and have shown that these mice are also protected against skeletal muscle and cardiac insulin resistance induced by high fat feeding (8; 9).
Although MCD inhibition protects against acute disease, due to the suggestion that impaired mitochondrial fatty acid oxidative capacity can contribute to disease progression in the elderly (3; 4) , it became important to determine the potential consequences of lifelong MCD deficiency on whole body physiology, which was examined in aged MCD-/-mice and their wild type (WT) littermates.
RESEARCH DESIGN AND METHODS

Animal Studies
All animals received care according to the Canadian Council on Animal Care and the University of Alberta Health Sciences Animal Welfare Committee. MCD-/-mice and their WT littermates were placed on a standard chow/low fat diet (4% kcal from lard) and separated into two cohorts.
In the first cohort, WT and MCD-/-mice were monitored until death to determine average lifespan. In the second cohort, male WT and MCD-/-mice at 70-75 wks of age were subjected to a number of experimental procedures described below. In a separate study, 16-month-old C57BL/6J mice were treated with either vehicle control or an MCD inhibitor (CBM-3001106 dissolved in a 1:1:1:7 mixture of ethanol:dimethylsulfoxide:cremophore:water, 10 mg/kg via daily oral gavage for 4 weeks) and subjected to a number of experimental procedures described below. Once all in vivo physiological parameters were assessed, animals were euthanized via an intraperitoneal injection of sodium pentobarbital (12 mg) in the random fed state 4 hrs into their dark cycle. Tissues were excised and immediately frozen in liquid N 2 for biochemical analyses.
Palmitate Oxidation Rates
A separate cohort of WT and MCD-/-mice were treated with either vehicle control or CBM-3001106 (10 mg/kg) via oral gavage once daily for 2 days (injections at 5:00 pm). The following morning mice were euthanized and hearts extracted for isolated working heart perfusion with 5 mM glucose and 0.4 mM [9,10- 3 H]palmitate bound to 3% bovine serum albumin, and palmitate oxidation rates were assessed as previously described (10) .
Glucose/Pyruvate/Insulin Tolerance Tests
Glucose, pyruvate, and insulin tolerance tests were performed 6 hr after food withdrawal in mice using glucose, pyruvate and insulin doses of 2 g/kg, 2 g/kg, and 0.7 U/kg, respectively. Plasma insulin concentrations were determined via use of a commercially available kit (Alpco Diagnostics) as previously described (11) .
Whole body In Vivo Metabolic Assessment and Exercise Tolerance
In vivo metabolic assessment via indirect calorimetry was performed using the Oxymax CLAMS (Columbus Instruments). Animals were initially acclimatized in the system for a 24 hr period, the subsequent 24 hr period was utilized for data collection. Exercise capacity was performed by running animals on a calibrated, motor-driven treadmill (Columbus Instruments) as previously described (12) .
Enzyme Activity Assays
Citrate synthase activity was determined in frozen gastrocnemius (10 mg) as previously described (12) . PDH activity was determined in frozen gastrocnemius (20 mg) using a radiometric assay described by Constantin-Teodosiu et al. (13) .
Determination of Lipid Intermediates
Tissue TAGs were extracted with a 2:1 chloroform-methanol solution and quantified with a commercially available enzymatic assay kit (Roche), whereas DAGs were extracted in 0. protease and phosphatase inhibitors (Sigma), and subjecting to Western blotting protocols as previously described (11) . Primary antibodies were prepared in a 1/1000 dilution in 5% BSA.
Immunoprecipitation with anti-acetyl-lysine antibodies followed by Western blotting methods was also used to detect overall protein acetylation and superoxide dismutase 2 (SOD2) acetylation as previously described (14) .
Protein Carbonylation and Lipid Peroxidation
Protein carbonylation was assessed in gastrocnemius muscle and liver extracts following instructions from a kit from Millipore (S7150). Overall carbonylation was normalized against β-actin protein expression. Lipid peroxidation was assessed in gastrocnemius muscle extracts following the instructions from a lipid hydroperoxide assay kit from Millipore (437639).
Statistical Analysis
All values are presented as mean ± standard error (SE). The significance of differences was determined by the use of a Kaplan Meier survival analysis, an unpaired two-tailed Student's t-test, or a two-way analysis of variance (ANOVA) followed by a Bonferroni post-hoc analysis where appropriate.
RESULTS
Increased Malonyl CoA Content in Aged MCD-/-Mice is Associated with a Substrate
Switch in Metabolism.
As predicted based on the increase in malonyl CoA content in muscle and liver ( Figure   1A /B), use of a comprehensive lab animal monitoring system (CLAMS) revealed that whole body fatty acid oxidation rates are decreased in aged MCD-/-mice, evidenced by the reduction in whole body oxygen consumption rates and elevation in respiratory exchange ratio ( Figure 1C /D).
Further support for a reduction in fatty acid oxidation rates in aged MCD-/-mice was also seen during aerobic isolated working heart perfusion experiments, where a significant decrease in palmitate oxidation rates was observed ( Figure 1E ). Consistent with a fuel substrate switch favoring carbohydrate oxidation, gastrocnemius muscle pyruvate dehydrogenase (PDH) activity, the rate-limiting enzyme of glucose oxidation, was elevated in aged MCD-/-mice ( Figure 1F 
MCD Inhibition Decreases Muscle Acetylation and Improves Age-Related Impairments in
Glycemic Control.
Recent studies have suggested that in addition to controlling fatty acid oxidation rates via malonyl CoA, MCD may also function as an acetylase (16) . In support of this, similar to SOD2 acetylation, overall protein acetylation was also reduced in gastrocnemius muscle from aged MCD-/-mice (Supplementary Figure 7) . Moreover, we treated C2C12 myotubes with an MCD
Page 9 of 40 Diabetes
inhibitor (CBM-3001106, 10 µM) that we previously showed to decrease fatty acid oxidation rates (17) , and observed a decrease in overall protein acetylation ( Figure 
DISCUSSION
Recent studies postulate that decreased mitochondrial fatty acid oxidation is responsible for the accumulation of intracellular lipid intermediates that contribute to the development of numerous chronic diseases in the elderly (3; 18). Therefore, MCD-/-mice, which have decreased fatty acid oxidation rates should be at an increased risk for developing insulin resistance, heart failure, and hepatic steatosis. All of these risks in combination would be expected to shorten the overall lifespan of these animals.
In contrast, MCD-/-mice displayed a significant increase in lifespan of ~30%, which was unexpected based on their lower overall fatty acid oxidative capacity. However, it is important to note that our n number for these experiments is not optimal for a true lifespan study, despite our findings being statistically significant (19) . Nevertheless, the critical observation that must be highlighted from our study is that we did not observe any premature metabolic disease development or early death in MCD-/-mice, despite the accumulation of lipid intermediates in key metabolic tissues. Indeed, we observed a strong trend towards an increase in muscle DAG content, which numerous studies have implicated as a key lipid intermediate in mediating
skeletal muscle insulin resistance (20) . Despite this trend, glucose tolerance was not worse in aged MCD-/-mice, and their age-related impairment in insulin tolerance was not as severe in comparison to their WT littermates. This may be due to the fact that muscle ceramide content was not altered in aged MCD-/-mice, and we (12) and others (21) have shown that increased ceramide content is a key factor precipitating skeletal muscle insulin resistance. With regards to insulin signaling, the aging-associated reduction in skeletal muscle and hepatic Akt and GSK3β phosphorylation were comparable in aged MCD-/-mice versus their aged WT littermates, but these findings would be strengthened if measured in the fasted and insulin-stimulated state (our assessment was carried out in tissues from animals sacrificed 4 hrs into their dark cycle).
Our findings in aged MCD-/-mice are not meant to insinuate that the accumulation of tissue lipid intermediates does not cause insulin resistance, as there is a mounting body of evidence supporting that ceramide and DAG are critical to the pathogenesis of insulin resistance (22) (23) (24) .
However, it is likely that some other factor or mechanism outweighs the harmful effects of increased lipid intermediates, and somehow protects aged MCD-/-mice from developing metabolic disease. Indeed, we have previously shown that young MCD-/-mice are actually protected from obesity-induced skeletal muscle insulin resistance, which may arise from a reduction in the incomplete oxidation of fatty acids observed during obesity (9). Thus, it is possible that incomplete fatty acid oxidation contributes to the insulin resistance in elderly patients, and may explain why the age-related impairment in insulin tolerance is not as severe in Another significant concern with reductions in fatty acid oxidation in the elderly population is that it may increase their risk of developing hepatic steatosis and non-alcoholic fatty liver disease (20) . Although hepatic TAG content was greater in aged MCD-/-mice, they had a Page 12 of 40 Diabetes subsequent reduction in hepatic DAG content. This finding is of particular interest, as DAG accumulation has been proposed to be a key player in the development of hepatic insulin resistance observed in elderly patients and those with type 2 diabetes (20) . These differences we observed with regards to DAG content in the muscle and liver illustrate and support the notion that the most powerful effect of lowering DAG content to improve insulin sensitivity appears to take place in the liver (26) . To our surprise, despite this marked lowering in hepatic DAG content, the reduction in oxidative stress in aged MCD-/-mice was only observed in skeletal muscle and not the liver. However, these findings do not rule out the decreased hepatic DAG content contributing to the overall metabolic health benefits seen in aged MCD-/-mice.
Since our findings in MCD-/-mice could potentially be model-specific and due to compensatory adaptations to global MCD deletion throughout development, we examined the effect of CBM-3001106, an MCD inhibitor, in aged mice. Our findings in this study are the first ever published in vivo findings with this MCD inhibitor, and similar to genetic MCD deficiency, we observed protection against age-related insulin resistance with pharmacological MCD inhibition. On the contrary, we also observed protection against glucose intolerance following pharmacological MCD inhibition. Reasons for this discrepancy between our genetic and pharmacological data are unclear at the moment, but could be due to the fact that pharmacological MCD inhibition produces robust effects on both inhibition of fatty acid oxidation and stimulation of glucose oxidation (6), whereas genetic MCD deficiency produces a metabolic phenotype that only becomes apparent under metabolic stress (7; 8). Nevertheless, in spite of these minor discrepancies, a key critical take-home message from our findings is that an inhibition of fatty acid oxidation, either via genetic or pharmacological MCD inhibition, does not worsen age-related metabolic disease as would be predicted based on current dogma (3; 20; 24).
Of interest, our results support the recent suggestion that MCD may be a bifunctional enzyme that also acts as an acetylase regulating protein acetylation (16) . However, our findings do not confirm whether MCD acts as an acetylase itself, or simply controls protein acetylation via controlling acetyl CoA content (Supplementary Figure 9) . It will be important for future studies to investigate this further, and determine whether our MCD inhibitor, CBM-3001106, which inhibits MCD's decarboxylase activity, also reduces protein acetylation via inhibiting an independent acetylase activity of MCD. We believe that the reduced protein acetylation following treatment with CBM-3001106 is likely a result of a reduction in acetyl CoA supply for mitochondrial acetylases (Supplementary Figure 9) . Indeed, MCD localizes to both the mitochondria and peroxisomes (5), and one target we observed to have lower acetylation following genetic or pharmacological MCD inhibition, SOD2, primarily localizes to the mitochondria in mammals (27) . Our results are limited though by encompassing measurements of acetylation in whole cellular extracts versus mitochondrial extracts, which would be the important compartment to measure regarding SOD2 acetylation. In spite of this limitation, because ~95% of acetyl CoA, which is the substrate for protein acetylation, is localized to the mitochondria (28), we do believe our total protein and SOD2 acetylation results likely reflect changes within the mitochondrial compartment. Furthermore, the deacetylases that regulate SOD2 acetylation, such as SIRT3, are also regulated via nicotinamide adenine dinucleotide (NAD+) levels (29) . Although muscle SIRT3 protein expression was similar in aged MCD-/-mice, our future studies will need to measure mitochondrial NAD+ content specifically, which may potentially mediate the observed changes in SOD2 acetylation by increasing SIRT3 activity.
To our surprise, the observed changes in gastrocnemius protein acetylation were not observed in livers from aged MCD-/-mice or aged mice treated with CBM-3001106. We are not certain why such changes would only be observed in the muscle and not the liver following MCD deficiency and/or inhibition, but could be related to our finding that MCD protein expression is only increased in muscle during aging, but not in the liver (Supplementary Figure   10) . In addition, it should be noted though that our acetylation results were completed via immunoprecipitation with anti-acetyl-lysine antibodies followed by immunoblotting techniques with an SOD2 antibody to detect SOD2 acetylation. Thus, more sophisticated proteome techniques that examine protein-specific changes to the acetylome are necessary before we can truly say that MCD inhibition also affects protein acetylation, in addition to reducing fatty acid oxidation.
In conclusion, our data challenges the hypothesis that decreased fat oxidation accelerates the progression of age-related diseases. Instead, we demonstrate that life-long whole body deficiency of MCD is associated with normal insulin sensitivity, decreased whole body fatty acid oxidation, increased whole body carbohydrate utilization, and normal liver function. Furthermore, pharmacological MCD inhibition produced marked improvements in glucose homeostasis in aged mice, though it will be important to in future studies to determine whether MCD inhibition improves glucose homeostasis in aged obese animals, as the world's elderly population is frequently also overweight and/or obese. Preliminary studies in our laboratory suggest that pharmacological MCD inhibition also protects against obesity-induced insulin resistance in young mice (data not shown). Whether such findings will translate to aged obese mice remains to be determined, and with the combined elements of both aging and obesity leading to increases in organ lipid accumulation, MCD inhibition may not be favorable in this scenario. Nevertheless, our previous studies have shown that MCD inhibition and/or deficiency in young mice is associated with protection against ischemia/reperfusion injury (6; 7; 10) and high fat diet-induced insulin resistance (9), while even reducing appetite and body weight gain (15) . Taken together with our observations that MCD deficiency and/or inhibition appears to protect against age-related insulin resistance, we illustrate an important paradigm shift, whereby chronic inhibition of fatty acid oxidation does not exacerbate age-related disease, but may instead have overall metabolic health benefits in the elderly.
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